All terms
Investigator-Initiated Trial
A clinical trial where an individual investigator (typically academic) — not the device or drug manufacturer — holds the regulatory sponsor role and is responsible for IRB, IDE/IND, and conduct.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026
Definition
An Investigator-Initiated Trial (IIT) is a clinical study in which an individual investigator (almost always an academic clinician) acts as the regulatory sponsor under 21 CFR 312 (drug IND) or 812 (device IDE), holding all sponsor obligations for protocol design, IRB/IEC submission, regulatory submissions, AE reporting, and study conduct. Industry support is typically limited to product supply and a financial grant under an Investigator-Initiated Research (IIR) agreement. What the regulation says
21 CFR 312/812 sponsor-investigator obligations are the same as for industry sponsors — including IND/IDE filing, ICH E6 GCP compliance, IRB oversight, and AE reporting.
What this means in practice
IITs are an important evidence-generation channel for new use cases, expanded populations, and combination studies that the manufacturer is unlikely to fund directly. Compliance landmines arise when industry inadvertently exerts study-design control, which can convert the study into a manufacturer-sponsored trial with full PMA/labeling implications. Common pitfalls
- •Industry sponsors providing too much protocol input — risks reclassification of the study as manufacturer-sponsored.
- •Investigator-sponsors underestimating the regulatory burden they have assumed.
Primary references
3 sourcesLink health: 2 verified 1 bot-blocked· last checked 2026-05-09
FDA·1eCFR·1NIH·1
- 1
FDA — Investigator ResponsibilitiesBot-blockedFDAfda.gov
- 2
21 CFR 312 — Investigational New Drug ApplicationVerifiedeCFRecfr.gov
- 3
ClinicalTrials.govVerifiedNIHclinicaltrials.gov
Inline markers like [1] jump to the matching reference above.